Industry Research Reports

Home > Reports > Service & Software > Neuroimaging Software - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032

Neuroimaging Software - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032

Industry: Service & Software

Published Date: 2026-08-14

Pages: 206 Pages

Report ld: 6766694

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

biaoTi KEY FINDINGS

Europe has the densest specialist supplier base, while North America combines major imaging platforms with leading neurovascular and surgical-planning vendors

Stroke and cerebrovascular imaging remain commercially established applications, while neurodegenerative monitoring is becoming a more important source of incremental demand

MRI-based quantification is expanding from diagnostic assessment toward treatment eligibility, longitudinal monitoring and ARIA evaluation

Neuroimaging Software Market Size(US$)

CAGR 2026-2032

10.3%

Market Size,2032

USD 2,638

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 1,466 million

Market Forecast in 2032(Value)

US$ 2,638 million

CAGR

10.3%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global market for Neuroimaging Software was estimated to be worth US$ 1326 million in 2025 and is projected to reach US$ 2638 million, growing at a CAGR of 10.3% from 2026 to 2032.

Neuroimaging Software refers to specialized medical software used to process, quantify, visualize, interpret, and manage analytical outputs derived from imaging of the brain and central nervous system. The market primarily covers software applied to MRI and its advanced sequences, CT/CTA/CTP, PET, SPECT, and multimodal neuroimaging datasets. Core capabilities include image registration and correction, automated tissue and lesion segmentation, brain volumetry and morphometry, perfusion analysis, diffusion and tractography processing, functional brain mapping, molecular imaging quantification, longitudinal change assessment, AI-assisted abnormality detection, and structured reporting. Commercial products are delivered through on-premise workstations, server-based applications, cloud or SaaS platforms, identifiable advanced post-processing modules integrated into imaging environments, and specialized analytical platforms supporting clinical trials and neuroscience research. Neuroimaging Software is primarily used in stroke and cerebrovascular disease, Alzheimer’s disease and other neurodegenerative disorders, multiple sclerosis, neuro-oncology, epilepsy, neurosurgical planning, functional brain assessment, and CNS drug development. The market is characterized by a combination of regulated clinical software, specialized quantitative imaging tools, AI-enabled decision-support applications, and research-oriented commercial platforms.

biaoTi MARKET TRENDS

Neuroimaging Software is shifting from isolated post-processing tools and single-purpose algorithms toward integrated, multimodal and longitudinal analytical workflows. MRI remains central to quantitative brain analysis, while CT-based stroke applications, PET and SPECT quantification, diffusion imaging, functional MRI and multimodal fusion broaden the addressable clinical workflows. Product development is increasingly focused on automated segmentation, quantitative biomarkers, longitudinal comparison, structured reporting and cloud-enabled delivery rather than stand-alone visualization alone. The expansion of disease-modifying therapies for Alzheimer’s disease is also strengthening the role of quantitative MRI and treatment-safety monitoring. In August 2025, the U.S. FDA required an additional earlier MRI monitoring point for patients receiving lecanemab because of ARIA risk, reinforcing the importance of repeatable brain-image assessment during therapy. At the same time, consolidation is accelerating as larger imaging and digital-health groups acquire specialized analytical technologies: GE HealthCare completed its acquisition of icometrix in 2025, SyntheticMR completed its acquisition of Combinostics, and RadNet acquired Gleamer for integration into DeepHealth in March 2026.

MARKET SEGMENTATION

By Company

GE HealthCare
Siemens Healthineers
RapidAI
Viz.ai
Philips
Brainlab
Canon
Fujifilm
Brainomix
Bruker
Cortechs.ai
RadNet
Aidoc
ConcertAI
Qure.ai
United Imaging Intelligence
Shukun Technology
Infervision
Stryker
Nicolab
Avicenna.AI
Synaptive Medical
Quibim
Surgical Theater
mediaire
Qynapse
Thermo Fisher
Hermes Medical Solutions
Omniscient Neurotechnology
IQ-AI
Neurophet
LPIXEL
JLK
Brainreader
NordicNeuroLab
VUNO
Heuron
Coreline Soft
Cercare Medical

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Advanced Post-processing and Visualization
Quantitative Biomarkers and Volumetry
AI Detection
Molecular Neuroimaging Quantification
Others

Segment by Application

Stroke and Cerebrovascular Disease
Neurodegenerative Disease and Multiple Sclerosis
Neuro-oncology
Others

Segment by Category

On-premise
Cloud-based
Hybrid

Segment by Division

Clinical Diagnostic or Decision Support
Clinical Trial or Drug Development
Research Use Only
Others

biaoTi MARKET DYNAMICS

Drivers

Demand for Neuroimaging Software is being supported by the rising clinical need for faster and more standardized interpretation of complex neurological imaging, together with increasing use of quantitative biomarkers in stroke, dementia, multiple sclerosis, neuro-oncology and neurosurgical planning. Hospital systems are seeking tools that reduce manual measurement, improve consistency across readers and accelerate time-sensitive workflows, particularly in acute stroke. Another important driver is the growing role of imaging in treatment selection and safety monitoring for neurodegenerative therapies. FDA requirements for additional MRI monitoring during lecanemab therapy illustrate how imaging is becoming more closely connected to longitudinal therapeutic management rather than one-time diagnosis alone. CNS drug development also creates demand for standardized MRI and PET analysis across sites and time points, supporting specialized clinical-trial imaging and biomarker platforms.

Restraints

Market adoption remains constrained by fragmented reimbursement, lengthy hospital procurement cycles, regulatory requirements, interoperability issues and the cost of integrating analytical software into existing radiology and clinical workflows. Neuroimaging algorithms must also perform consistently across scanners, protocols, patient populations and imaging quality levels, increasing the cost of validation and product maintenance. In research-oriented applications, widely used academic and open-source software continues to limit pricing power for commercial vendors. Large imaging OEMs can also bundle advanced post-processing functions into broader workstation or enterprise-imaging contracts, which can reduce the addressable stand-alone software value for independent suppliers. These factors mean that technically strong products do not automatically translate into rapid commercial adoption, particularly where the clinical workflow benefit or reimbursement pathway is not clearly defined.

Opportunities

The most attractive opportunities are emerging where Neuroimaging Software moves beyond image visualization to support treatment pathways, measurable biomarkers and longitudinal disease management. Quantitative MRI for Alzheimer’s disease, ARIA assessment, automated brain volumetry, multiple-sclerosis monitoring, PET-based neurodegenerative biomarkers and treatment-response analysis are becoming increasingly relevant. CMS documentation on automated brain MRI detection and quantification identifies regulated commercial products for brain volumetry, ARIA analysis and morphometric assessment, demonstrating that these applications are moving toward identifiable clinical software categories. Additional opportunities exist in vendor-neutral cloud deployment, multimodal MRI/PET analysis, CNS clinical trials, smaller hospitals that lack specialist neuroradiology resources, and emerging Asian markets where domestic medical-AI suppliers are building localized neuroimaging products.

Challenges

The principal long-term challenge is converting algorithmic performance into repeatable clinical and economic value. Regulatory clearance alone does not guarantee reimbursement, workflow adoption or sustained usage, and suppliers must continuously demonstrate reliability across diverse populations and imaging environments. Competitive intensity is also rising as specialized algorithms become integrated into larger enterprise-imaging, AI-orchestration and scanner-vendor ecosystems. Consolidation may increase access to distribution while simultaneously reducing the number of independent purchasing decisions available to smaller vendors. Data privacy requirements, cross-border cloud deployment rules, cybersecurity expectations and evolving AI regulation add further complexity. The market therefore favors companies that can combine validated algorithms with clinical integration, scalable deployment, regulatory execution and durable relationships with hospitals or pharmaceutical customers.

biaoTi VALUE CHAIN ANALYSIS

The Neuroimaging Software value chain begins with medical imaging data, computational infrastructure, image-processing frameworks, anatomical atlases, clinically annotated datasets and algorithm-development capabilities. These inputs support the development of segmentation, registration, volumetric analysis, perfusion modeling, diffusion analysis, functional mapping, molecular imaging quantification and AI-based detection tools. The midstream layer consists of specialized software companies, medical-imaging OEMs, clinical AI developers, nuclear-medicine software providers, neurosurgical planning vendors and CNS imaging platforms. Products are commercialized through perpetual or term licenses, enterprise subscriptions, SaaS contracts, per-scan or usage-based models, OEM embedding arrangements and clinical-trial contracts.

Value is created when raw imaging data are converted into quantitative measurements, biomarkers, workflow prioritization, treatment-planning information or longitudinal evidence that improves decision consistency and reduces manual analytical work. Downstream users include hospitals, imaging centers, neurology and neurosurgery departments, pharmaceutical and biotechnology companies, CROs and research institutions. Cost structures are dominated by software R&D, clinical validation, regulatory compliance, data acquisition and curation, cloud infrastructure, cybersecurity, integration, sales and implementation. As deployment moves toward recurring SaaS and enterprise models, scalable software economics become more important, but clinical support, integration and regulatory maintenance remain meaningful cost components.

biaoTi SEGMENT INSIGHTS

From a product-function perspective, the market contains several commercially meaningful segments rather than a single homogeneous software category. Acute stroke and neurovascular analysis is one of the most established clinical applications because software outputs can be integrated directly into time-sensitive emergency workflows. Advanced post-processing and visualization also represent an established installed-base segment through major imaging vendors. Quantitative brain MRI, neurodegenerative disease assessment and longitudinal biomarker analysis are gaining strategic importance as neurological treatment pathways increasingly require repeatable measurements rather than qualitative interpretation alone. MRI-related applications represent the broadest product coverage across the identified supplier universe, spanning structural volumetry, diffusion imaging, functional mapping, perfusion, multiple-sclerosis analysis and neuro-oncology.

The fastest-evolving opportunity set is concentrated around quantitative and treatment-linked applications rather than basic image viewing. Automated brain segmentation, hippocampal and regional volumetry, cortical and lesion measurement, ARIA assessment and longitudinal change analysis are becoming increasingly differentiated commercial functions. CMS documentation recognizes multiple FDA-cleared products addressing automated labeling, visualization and volumetric quantification of brain MRI, as well as dedicated ARIA analysis, supporting the emergence of a more defined regulated quantitative-neuroimaging segment. Functional MRI, DTI, tractography, connectomics and molecular neuroimaging remain smaller but technically differentiated segments with strong relevance in neurosurgery, research and CNS drug development.

biaoTi DOWNSTREAM MARKET OPPORTUNITIES

Hospitals and diagnostic imaging centers remain the primary commercial users of Neuroimaging Software, but the demand profile is widening beyond the radiology department. Stroke centers require rapid neurovascular triage and perfusion analysis, neurology services increasingly use quantitative MRI for neurodegenerative and demyelinating diseases, and neurosurgical teams require multimodal fusion, tractography and functional mapping for preoperative planning. Pharmaceutical and biotechnology companies represent an increasingly strategic downstream opportunity because CNS drug programs depend on standardized longitudinal imaging biomarkers, patient stratification and safety monitoring. This creates room for software suppliers that can bridge routine clinical imaging and research-grade quantitative analysis. Smaller hospitals and imaging networks also represent an underpenetrated opportunity as cloud-based deployment reduces the need for dedicated local workstations and specialist post-processing resources.

biaoTi REGIONAL INSIGHTS

Fastest-Growing Region: Asia Pacific

Europe has the largest concentration of identified independent specialist Neuroimaging Software suppliers, particularly in quantitative brain MRI, perfusion, nuclear medicine, functional imaging and neurodegenerative disease analysis. The region combines established medical-imaging technology clusters with a relatively broad base of smaller specialist developers. North America has a different competitive structure: major imaging and digital-health platforms coexist with commercially advanced stroke-AI, neurosurgical planning, quantitative imaging and research-software providers. The region remains particularly important for regulated clinical commercialization because FDA clearance, large hospital networks and pharmaceutical demand can support broader deployment of successful products. CMS activity around automated brain MRI quantification also highlights increasing attention to the clinical and reimbursement framework for quantitative neuroimaging.

XX.X
%
CAGR*
XXXX
US$ Million
XXXX
REGIONAL SHARE

BY TYPE,2021-2032(US $ MILLION)

Advanced Post-processing and Visualization

Quantitative Biomarkers and Volumetry

AI Detection

Molecular Neuroimaging Quantification

Others

BY APPLICATION，2021-2032(US $ MILLION）

Stroke and Cerebrovascular Disease

Neurodegenerative Disease and Multiple Sclerosis

Neuro-oncology

Others

Asia-Pacific is becoming more strategically important but remains structurally fragmented. Japan combines global imaging OEMs with domestic neurological AI developers, while South Korea has developed a relatively dense cluster of specialist brain-imaging AI companies focused on volumetry, stroke, Parkinson’s disease, intracranial hemorrhage and cerebrovascular analysis. China has a growing medical-AI ecosystem, although the stricter product-evidence standard applied in this study results in a smaller Core Formal List than in Europe or North America. Taiwan and Australia contribute several niche vendors in diffusion MRI, brain metastasis analysis, perfusion and quantitative neuroimaging. The regional opportunity therefore lies less in simple geographic expansion and more in localization, regulatory approval, hospital integration and adaptation to country-specific clinical workflows.

biaoTi COMPETITIVE LANDSCAPE ANALYSIS

The Neuroimaging Software market has a layered competitive structure rather than a single group of directly comparable competitors. Major imaging OEMs compete through scanner installed bases, integrated workstations, enterprise-imaging relationships and global distribution, while independent specialists compete through deeper algorithms and clinical focus in stroke, brain volumetry, neurodegeneration, perfusion, molecular imaging, fMRI/DTI, neuro-oncology and neurosurgical planning. The study identifies 61 companies in the Core Formal List, demonstrating that the commercially relevant supplier base extends well beyond a small group of global imaging companies. Competitive consolidation is increasing as larger platforms acquire specialized software capabilities. GE HealthCare closed its acquisition of icometrix in 2025 to strengthen neurological MRI analysis, SyntheticMR acquired Combinostics to broaden quantitative neuroimaging capabilities, and RadNet acquired Gleamer in 2026 to expand DeepHealth’s clinical AI portfolio. These transactions point toward continued integration of specialist algorithms into broader imaging ecosystems, but highly differentiated areas such as ARIA quantification, connectomics, advanced perfusion, molecular imaging and functional brain mapping continue to provide defensible positions for focused vendors.

biaoTi REPORT SCOPE

This report provides a comprehensive view of the global market for Neuroimaging Software, covering total sales revenue, the market share and ranking of key companies, along with analyses by region & country, by Type, and by Application.

The Neuroimaging Software market size, estimations, and forecasts are presented in terms of sales revenue ($ millions), with 2025 as the base year and historical and forecast data from 2021 to 2032. The report combines quantitative and qualitative analysis to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current marketplace, and make informed business decisions regarding Neuroimaging Software.

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the scope of the report and the global market size (value). It also summarizes market dynamics and recent developments; identifies key drivers and restraints; outlines challenges and risks for players; reviews relevant industry policies.

Chapter 2: Provides a detailed analysis of the Neuroimaging Software companies' competitive landscape—including revenue shares, recent development plans, and mergers and acquisitions (M&A).

Chapter 3: Analyzes market segmentation by Type, presenting the size and growth potential of each segment to help readers identify blue-ocean opportunities.

Chapter 4: Analyzes market segmentation by Application, presenting the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.

Chapter 5: Presents Neuroimaging Software revenue at the regional level. It offers a quantitative assessment of market size and growth potential by region and summarizes market development, future prospects, addressable space, and country-level market size worldwide.

Chapter 6: Presents Neuroimaging Software revenue at the country level. It provides segmented data by Type and by Application for each country/region.

Chapter 7: Profiles key players, detailing the main companies' product revenue, gross margin, product portfolios, recent developments, etc.

Chapter 8: Analysis of Value Chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 Neuroimaging Software Product Introduction

1.2 Global Neuroimaging Software Market Size Forecast (2021–2032)

1.3 Neuroimaging Software Market Trends & Drivers

1.3.1 Neuroimaging Software Industry Trends

1.3.2 Neuroimaging Software Market Drivers & Opportunities

1.3.3 Neuroimaging Software Market Challenges

1.3.4 Neuroimaging Software Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Neuroimaging Software Players Revenue Ranking (2025)

2.2 Global Neuroimaging Software Revenue by Company (2021–2026)

2.3 Key Companies’ R&D and Operations Footprint and Headquarters

2.4 Key Companies Neuroimaging Software Product Offerings

2.5 Key Companies General Availability (GA) Timeline for Neuroimaging Software

2.6 Neuroimaging Software Market Competitive Analysis

2.6.1 Neuroimaging Software Market Concentration Rate (2021–2026)

2.6.2 Top 5 and Top 10 Global Companies by Neuroimaging Software Revenue in 2025

2.6.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Neuroimaging Software revenue, 2025

2.7 Mergers & Acquisitions and Expansion

3 Segmentation Neuroimaging Software Market Classification

3.1 Introduction by Type

3.1.1 Advanced Post-processing and Visualization

3.1.2 Quantitative Biomarkers and Volumetry

3.1.3 AI Detection

3.1.4 Molecular Neuroimaging Quantification

3.1.5 Others

3.1.6 Global Neuroimaging Software Sales Value by Type

3.1.6.1 Global Neuroimaging Software Sales Value by Type (2021 vs 2025 vs 2032)

3.1.6.2 Global Neuroimaging Software Sales Value, by Type (2021–2032)

3.1.6.3 Global Neuroimaging Software Sales Value, by Type (%), 2021–2032

3.2 Introduction by Deployment Model

3.2.1 On-premise

3.2.2 Cloud-based

3.2.3 Hybrid

3.2.4 Global Neuroimaging Software Sales Value by Deployment Model

3.2.4.1 Global Neuroimaging Software Sales Value by Deployment Model (2021 vs 2025 vs 2032)

3.2.4.2 Global Neuroimaging Software Sales Value, by Deployment Model (2021–2032)

3.2.4.3 Global Neuroimaging Software Sales Value, by Deployment Model (%), 2021–2032

3.3 Introduction by Intended Use

3.3.1 Clinical Diagnostic or Decision Support

3.3.2 Clinical Trial or Drug Development

3.3.3 Research Use Only

3.3.4 Others

3.3.5 Global Neuroimaging Software Sales Value by Intended Use

3.3.5.1 Global Neuroimaging Software Sales Value by Intended Use (2021 vs 2025 vs 2032)

3.3.5.2 Global Neuroimaging Software Sales Value, by Intended Use (2021–2032)

3.3.5.3 Global Neuroimaging Software Sales Value, by Intended Use (%), 2021–2032

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Stroke and Cerebrovascular Disease

4.1.2 Neurodegenerative Disease and Multiple Sclerosis

4.1.3 Neuro-oncology

4.1.4 Others

4.2 Global Neuroimaging Software Sales Value by Application

4.2.1 Global Neuroimaging Software Sales Value by Application (2021 vs 2025 vs 2032)

4.2.2 Global Neuroimaging Software Sales Value by Application (2021–2032)

4.2.3 Global Neuroimaging Software Sales Value by Application (%), 2021–2032

5 Segmentation by Region

5.1 Global Neuroimaging Software Sales Value by Region

5.1.1 Global Neuroimaging Software Sales Value by Region: 2021 vs 2025 vs 2032

5.1.2 Global Neuroimaging Software Sales Value by Region (2021–2026)

5.1.3 Global Neuroimaging Software Sales Value by Region (2027–2032)

5.1.4 Global Neuroimaging Software Sales Value by Region (%), 2021–2032

5.2 North America

5.2.1 North America Neuroimaging Software Sales Value, 2021–2032

5.2.2 North America Neuroimaging Software Sales Value by Country (%), 2025 vs 2032

5.3 Europe

5.3.1 Europe Neuroimaging Software Sales Value, 2021–2032

5.3.2 Europe Neuroimaging Software Sales Value by Country (%), 2025 vs 2032

5.4 Asia Pacific

5.4.1 Asia Pacific Neuroimaging Software Sales Value, 2021–2032

5.4.2 Asia Pacific Neuroimaging Software Sales Value by Subregion (%), 2025 vs 2032

5.5 South America

5.5.1 South America Neuroimaging Software Sales Value, 2021–2032

5.5.2 South America Neuroimaging Software Sales Value by Country (%), 2025 vs 2032

5.6 Middle East & Africa

5.6.1 Middle East & Africa Neuroimaging Software Sales Value, 2021–2032

5.6.2 Middle East & Africa Neuroimaging Software Sales Value by Country (%), 2025 vs 2032

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Neuroimaging Software Sales Value Growth Trends, 2021 vs 2025 vs 2032

6.2 Key Countries/Regions Neuroimaging Software Sales Value, 2021–2032

6.3 United States

6.3.1 United States Neuroimaging Software Sales Value, 2021–2032

6.3.2 United States Neuroimaging Software Sales Value by Type (%), 2025 vs 2032

6.3.3 United States Neuroimaging Software Sales Value by Application, 2025 vs 2032

6.4 Europe

6.4.1 Europe Neuroimaging Software Sales Value, 2021–2032

6.4.2 Europe Neuroimaging Software Sales Value by Type (%), 2025 vs 2032

6.4.3 Europe Neuroimaging Software Sales Value by Application, 2025 vs 2032

6.5 China

6.5.1 China Neuroimaging Software Sales Value, 2021–2032

6.5.2 China Neuroimaging Software Sales Value by Type (%), 2025 vs 2032

6.5.3 China Neuroimaging Software Sales Value by Application, 2025 vs 2032

6.6 Japan

6.6.1 Japan Neuroimaging Software Sales Value, 2021–2032

6.6.2 Japan Neuroimaging Software Sales Value by Type (%), 2025 vs 2032

6.6.3 Japan Neuroimaging Software Sales Value by Application, 2025 vs 2032

6.7 South Korea

6.7.1 South Korea Neuroimaging Software Sales Value, 2021–2032

6.7.2 South Korea Neuroimaging Software Sales Value by Type (%), 2025 vs 2032

6.7.3 South Korea Neuroimaging Software Sales Value by Application, 2025 vs 2032

6.8 Southeast Asia

6.8.1 Southeast Asia Neuroimaging Software Sales Value, 2021–2032

6.8.2 Southeast Asia Neuroimaging Software Sales Value by Type (%), 2025 vs 2032

6.8.3 Southeast Asia Neuroimaging Software Sales Value by Application, 2025 vs 2032

6.9 India

6.9.1 India Neuroimaging Software Sales Value, 2021–2032

6.9.2 India Neuroimaging Software Sales Value by Type (%), 2025 vs 2032

6.9.3 India Neuroimaging Software Sales Value by Application, 2025 vs 2032

7 Company Profiles

7.1 GE HealthCare

7.1.1 GE HealthCare Profile

7.1.2 GE HealthCare Main Business

7.1.3 GE HealthCare Neuroimaging Software Products, Services, and Solutions

7.1.4 GE HealthCare Neuroimaging Software Revenue (US$ Million), 2021–2026

7.1.5 GE HealthCare Recent Developments

7.2 Siemens Healthineers

7.2.1 Siemens Healthineers Profile

7.2.2 Siemens Healthineers Main Business

7.2.3 Siemens Healthineers Neuroimaging Software Products, Services, and Solutions

7.2.4 Siemens Healthineers Neuroimaging Software Revenue (US$ Million), 2021–2026

7.2.5 Siemens Healthineers Recent Developments

7.3 RapidAI

7.3.1 RapidAI Profile

7.3.2 RapidAI Main Business

7.3.3 RapidAI Neuroimaging Software Products, Services, and Solutions

7.3.4 RapidAI Neuroimaging Software Revenue (US$ Million), 2021–2026

7.3.5 RapidAI Recent Developments

7.4 Viz.ai

7.4.1 Viz.ai Profile

7.4.2 Viz.ai Main Business

7.4.3 Viz.ai Neuroimaging Software Products, Services, and Solutions

7.4.4 Viz.ai Neuroimaging Software Revenue (US$ Million), 2021–2026

7.4.5 Viz.ai Recent Developments

7.5 Philips

7.5.1 Philips Profile

7.5.2 Philips Main Business

7.5.3 Philips Neuroimaging Software Products, Services, and Solutions

7.5.4 Philips Neuroimaging Software Revenue (US$ Million), 2021–2026

7.5.5 Philips Recent Developments

7.6 Brainlab

7.6.1 Brainlab Profile

7.6.2 Brainlab Main Business

7.6.3 Brainlab Neuroimaging Software Products, Services, and Solutions

7.6.4 Brainlab Neuroimaging Software Revenue (US$ Million), 2021–2026

7.6.5 Brainlab Recent Developments

7.7 Canon

7.7.1 Canon Profile

7.7.2 Canon Main Business

7.7.3 Canon Neuroimaging Software Products, Services, and Solutions

7.7.4 Canon Neuroimaging Software Revenue (US$ Million), 2021–2026

7.7.5 Canon Recent Developments

7.8 Fujifilm

7.8.1 Fujifilm Profile

7.8.2 Fujifilm Main Business

7.8.3 Fujifilm Neuroimaging Software Products, Services, and Solutions

7.8.4 Fujifilm Neuroimaging Software Revenue (US$ Million), 2021–2026

7.8.5 Fujifilm Recent Developments

7.9 Brainomix

7.9.1 Brainomix Profile

7.9.2 Brainomix Main Business

7.9.3 Brainomix Neuroimaging Software Products, Services, and Solutions

7.9.4 Brainomix Neuroimaging Software Revenue (US$ Million), 2021–2026

7.9.5 Brainomix Recent Developments

7.10 Bruker

7.10.1 Bruker Profile

7.10.2 Bruker Main Business

7.10.3 Bruker Neuroimaging Software Products, Services, and Solutions

7.10.4 Bruker Neuroimaging Software Revenue (US$ Million), 2021–2026

7.10.5 Bruker Recent Developments

7.11 Cortechs.ai

7.11.1 Cortechs.ai Profile

7.11.2 Cortechs.ai Main Business

7.11.3 Cortechs.ai Neuroimaging Software Products, Services, and Solutions

7.11.4 Cortechs.ai Neuroimaging Software Revenue (US$ Million), 2021–2026

7.11.5 Cortechs.ai Recent Developments

7.12 RadNet

7.12.1 RadNet Profile

7.12.2 RadNet Main Business

7.12.3 RadNet Neuroimaging Software Products, Services, and Solutions

7.12.4 RadNet Neuroimaging Software Revenue (US$ Million), 2021–2026

7.12.5 RadNet Recent Developments

7.13 Aidoc

7.13.1 Aidoc Profile

7.13.2 Aidoc Main Business

7.13.3 Aidoc Neuroimaging Software Products, Services, and Solutions

7.13.4 Aidoc Neuroimaging Software Revenue (US$ Million), 2021–2026

7.13.5 Aidoc Recent Developments

7.14 ConcertAI

7.14.1 ConcertAI Profile

7.14.2 ConcertAI Main Business

7.14.3 ConcertAI Neuroimaging Software Products, Services, and Solutions

7.14.4 ConcertAI Neuroimaging Software Revenue (US$ Million), 2021–2026

7.14.5 ConcertAI Recent Developments

7.15 Qure.ai

7.15.1 Qure.ai Profile

7.15.2 Qure.ai Main Business

7.15.3 Qure.ai Neuroimaging Software Products, Services, and Solutions

7.15.4 Qure.ai Neuroimaging Software Revenue (US$ Million), 2021–2026

7.15.5 Qure.ai Recent Developments

7.16 United Imaging Intelligence

7.16.1 United Imaging Intelligence Profile

7.16.2 United Imaging Intelligence Main Business

7.16.3 United Imaging Intelligence Neuroimaging Software Products, Services, and Solutions

7.16.4 United Imaging Intelligence Neuroimaging Software Revenue (US$ Million), 2021–2026

7.16.5 United Imaging Intelligence Recent Developments

7.17 Shukun Technology

7.17.1 Shukun Technology Profile

7.17.2 Shukun Technology Main Business

7.17.3 Shukun Technology Neuroimaging Software Products, Services, and Solutions

7.17.4 Shukun Technology Neuroimaging Software Revenue (US$ Million), 2021–2026

7.17.5 Shukun Technology Recent Developments

7.18 Infervision

7.18.1 Infervision Profile

7.18.2 Infervision Main Business

7.18.3 Infervision Neuroimaging Software Products, Services, and Solutions

7.18.4 Infervision Neuroimaging Software Revenue (US$ Million), 2021–2026

7.18.5 Infervision Recent Developments

7.19 Stryker

7.19.1 Stryker Profile

7.19.2 Stryker Main Business

7.19.3 Stryker Neuroimaging Software Products, Services, and Solutions

7.19.4 Stryker Neuroimaging Software Revenue (US$ Million), 2021–2026

7.19.5 Stryker Recent Developments

7.20 Nicolab

7.20.1 Nicolab Profile

7.20.2 Nicolab Main Business

7.20.3 Nicolab Neuroimaging Software Products, Services, and Solutions

7.20.4 Nicolab Neuroimaging Software Revenue (US$ Million), 2021–2026

7.20.5 Nicolab Recent Developments

7.21 Avicenna.AI

7.21.1 Avicenna.AI Profile

7.21.2 Avicenna.AI Main Business

7.21.3 Avicenna.AI Neuroimaging Software Products, Services, and Solutions

7.21.4 Avicenna.AI Neuroimaging Software Revenue (US$ Million), 2021–2026

7.21.5 Avicenna.AI Recent Developments

7.22 Synaptive Medical

7.22.1 Synaptive Medical Profile

7.22.2 Synaptive Medical Main Business

7.22.3 Synaptive Medical Neuroimaging Software Products, Services, and Solutions

7.22.4 Synaptive Medical Neuroimaging Software Revenue (US$ Million), 2021–2026

7.22.5 Synaptive Medical Recent Developments

7.23 Quibim

7.23.1 Quibim Profile

7.23.2 Quibim Main Business

7.23.3 Quibim Neuroimaging Software Products, Services, and Solutions

7.23.4 Quibim Neuroimaging Software Revenue (US$ Million), 2021–2026

7.23.5 Quibim Recent Developments

7.24 Surgical Theater

7.24.1 Surgical Theater Profile

7.24.2 Surgical Theater Main Business

7.24.3 Surgical Theater Neuroimaging Software Products, Services, and Solutions

7.24.4 Surgical Theater Neuroimaging Software Revenue (US$ Million), 2021–2026

7.24.5 Surgical Theater Recent Developments

7.25 mediaire

7.25.1 mediaire Profile

7.25.2 mediaire Main Business

7.25.3 mediaire Neuroimaging Software Products, Services, and Solutions

7.25.4 mediaire Neuroimaging Software Revenue (US$ Million), 2021–2026

7.25.5 mediaire Recent Developments

7.26 Qynapse

7.26.1 Qynapse Profile

7.26.2 Qynapse Main Business

7.26.3 Qynapse Neuroimaging Software Products, Services, and Solutions

7.26.4 Qynapse Neuroimaging Software Revenue (US$ Million), 2021–2026

7.26.5 Qynapse Recent Developments

7.27 Thermo Fisher

7.27.1 Thermo Fisher Profile

7.27.2 Thermo Fisher Main Business

7.27.3 Thermo Fisher Neuroimaging Software Products, Services, and Solutions

7.27.4 Thermo Fisher Neuroimaging Software Revenue (US$ Million), 2021–2026

7.27.5 Thermo Fisher Recent Developments

7.28 Hermes Medical Solutions

7.28.1 Hermes Medical Solutions Profile

7.28.2 Hermes Medical Solutions Main Business

7.28.3 Hermes Medical Solutions Neuroimaging Software Products, Services, and Solutions

7.28.4 Hermes Medical Solutions Neuroimaging Software Revenue (US$ Million), 2021–2026

7.28.5 Hermes Medical Solutions Recent Developments

7.29 Omniscient Neurotechnology

7.29.1 Omniscient Neurotechnology Profile

7.29.2 Omniscient Neurotechnology Main Business

7.29.3 Omniscient Neurotechnology Neuroimaging Software Products, Services, and Solutions

7.29.4 Omniscient Neurotechnology Neuroimaging Software Revenue (US$ Million), 2021–2026

7.29.5 Omniscient Neurotechnology Recent Developments

7.30 IQ-AI

7.30.1 IQ-AI Profile

7.30.2 IQ-AI Main Business

7.30.3 IQ-AI Neuroimaging Software Products, Services, and Solutions

7.30.4 IQ-AI Neuroimaging Software Revenue (US$ Million), 2021–2026

7.30.5 IQ-AI Recent Developments

7.31 Neurophet

7.31.1 Neurophet Profile

7.31.2 Neurophet Main Business

7.31.3 Neurophet Neuroimaging Software Products, Services, and Solutions

7.31.4 Neurophet Neuroimaging Software Revenue (US$ Million), 2021–2026

7.31.5 Neurophet Recent Developments

7.32 LPIXEL

7.32.1 LPIXEL Profile

7.32.2 LPIXEL Main Business

7.32.3 LPIXEL Neuroimaging Software Products, Services, and Solutions

7.32.4 LPIXEL Neuroimaging Software Revenue (US$ Million), 2021–2026

7.32.5 LPIXEL Recent Developments

7.33 JLK

7.33.1 JLK Profile

7.33.2 JLK Main Business

7.33.3 JLK Neuroimaging Software Products, Services, and Solutions

7.33.4 JLK Neuroimaging Software Revenue (US$ Million), 2021–2026

7.33.5 JLK Recent Developments

7.34 Brainreader

7.34.1 Brainreader Profile

7.34.2 Brainreader Main Business

7.34.3 Brainreader Neuroimaging Software Products, Services, and Solutions

7.34.4 Brainreader Neuroimaging Software Revenue (US$ Million), 2021–2026

7.34.5 Brainreader Recent Developments

7.35 NordicNeuroLab

7.35.1 NordicNeuroLab Profile

7.35.2 NordicNeuroLab Main Business

7.35.3 NordicNeuroLab Neuroimaging Software Products, Services, and Solutions

7.35.4 NordicNeuroLab Neuroimaging Software Revenue (US$ Million), 2021–2026

7.35.5 NordicNeuroLab Recent Developments

7.36 VUNO

7.36.1 VUNO Profile

7.36.2 VUNO Main Business

7.36.3 VUNO Neuroimaging Software Products, Services, and Solutions

7.36.4 VUNO Neuroimaging Software Revenue (US$ Million), 2021–2026

7.36.5 VUNO Recent Developments

7.37 Heuron

7.37.1 Heuron Profile

7.37.2 Heuron Main Business

7.37.3 Heuron Neuroimaging Software Products, Services, and Solutions

7.37.4 Heuron Neuroimaging Software Revenue (US$ Million), 2021–2026

7.37.5 Heuron Recent Developments

7.38 Coreline Soft

7.38.1 Coreline Soft Profile

7.38.2 Coreline Soft Main Business

7.38.3 Coreline Soft Neuroimaging Software Products, Services, and Solutions

7.38.4 Coreline Soft Neuroimaging Software Revenue (US$ Million), 2021–2026

7.38.5 Coreline Soft Recent Developments

7.39 Cercare Medical

7.39.1 Cercare Medical Profile

7.39.2 Cercare Medical Main Business

7.39.3 Cercare Medical Neuroimaging Software Products, Services, and Solutions

7.39.4 Cercare Medical Neuroimaging Software Revenue (US$ Million), 2021–2026

7.39.5 Cercare Medical Recent Developments

8 Industry Chain Analysis

8.1 Neuroimaging Software Value Chain

8.2 Neuroimaging Software Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Key Suppliers of Raw Materials

8.2.3 Cost Structure

8.3 Midstream Analysis

8.4 Downstream (Customer) Analysis

8.5 Sales Model and Sales Channelss

8.5.1 Neuroimaging Software Sales Model

8.5.2 Sales Channels

8.5.3 Neuroimaging Software Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Neuroimaging Software Market Trends

Table 2. Neuroimaging Software Market Drivers & Opportunities

Table 3. Neuroimaging Software Market Challenges

Table 4. Neuroimaging Software Market Restraints

Table 5. Global Neuroimaging Software Revenue by Company (US$ Million), 2021–2026

Table 6. Global Neuroimaging Software Revenue Market Share by Company (2021–2026)

Table 7. Key Companies’ R&D and Operations Footprint and Headquarters

Table 8. Key Companies Neuroimaging Software Product Type

Table 9. Key Companies General Availability (GA) Timeline for Neuroimaging Software

Table 10. Global Neuroimaging Software Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Neuroimaging Software revenue, 2025

Table 12. Mergers & Acquisitions and Expansion Plans

Table 13. Global Neuroimaging Software Sales Value by Type: 2021 vs 2025 vs 2032 (US$ Million)

Table 14. Global Neuroimaging Software Sales Value by Type (US$ Million), 2021–2026

Table 15. Global Neuroimaging Software Sales Value by Type (US$ Million), 2027–2032

Table 16. Global Neuroimaging Software Sales Market Share in Value by Type (2021–2026)

Table 17. Global Neuroimaging Software Sales Market Share in Value by Type (2027–2032)

Table 18. Global Neuroimaging Software Sales Value by Deployment Model: 2021 vs 2025 vs 2032 (US$ Million)

Table 19. Global Neuroimaging Software Sales Value by Deployment Model (US$ Million), 2021–2026

Table 20. Global Neuroimaging Software Sales Value by Deployment Model (US$ Million), 2027–2032

Table 21. Global Neuroimaging Software Sales Market Share in Value by Deployment Model (2021–2026)

Table 22. Global Neuroimaging Software Sales Market Share in Value by Deployment Model (2027–2032)

Table 23. Global Neuroimaging Software Sales Value by Intended Use: 2021 vs 2025 vs 2032 (US$ Million)

Table 24. Global Neuroimaging Software Sales Value by Intended Use (US$ Million), 2021–2026

Table 25. Global Neuroimaging Software Sales Value by Intended Use (US$ Million), 2027–2032

Table 26. Global Neuroimaging Software Sales Market Share in Value by Intended Use (2021–2026)

Table 27. Global Neuroimaging Software Sales Market Share in Value by Intended Use (2027–2032)

Table 28. Global Neuroimaging Software Sales Value by Application: 2021 vs 2025 vs 2032 (US$ Million)

Table 29. Global Neuroimaging Software Sales Value by Application (US$ Million), 2021–2026

Table 30. Global Neuroimaging Software Sales Value by Application (US$ Million), 2027–2032

Table 31. Global Neuroimaging Software Sales Market Share in Value by Application (2021–2026)

Table 32. Global Neuroimaging Software Sales Market Share in Value by Application (2027–2032)

Table 33. Global Neuroimaging Software Sales Value by Region, (US$ Million), 2021 vs 2025 vs 2032

Table 34. Global Neuroimaging Software Sales Value by Region (US$ Million), 2021–2026

Table 35. Global Neuroimaging Software Sales Value by Region (US$ Million), 2027–2032

Table 36. Global Neuroimaging Software Sales Value by Region (%), 2021–2026

Table 37. Global Neuroimaging Software Sales Value by Region (%), 2027–2032

Table 38. Key Countries/Regions Neuroimaging Software Sales Value Growth Trends, (US$ Million): 2021 vs 2025 vs 2032

Table 39. Key Countries/Regions Neuroimaging Software Sales Value, (US$ Million), 2021–2026

Table 40. Key Countries/Regions Neuroimaging Software Sales Value, (US$ Million), 2027–2032

Table 41. GE HealthCare Basic Information List

Table 42. GE HealthCare Description and Business Overview

Table 43. GE HealthCare Neuroimaging Software Products, Services, and Solutions

Table 44. Revenue (US$ Million) in Neuroimaging Software Business of GE HealthCare (2021–2026)

Table 45. GE HealthCare Recent Developments

Table 46. Siemens Healthineers Basic Information List

Table 47. Siemens Healthineers Description and Business Overview

Table 48. Siemens Healthineers Neuroimaging Software Products, Services, and Solutions

Table 49. Revenue (US$ Million) in Neuroimaging Software Business of Siemens Healthineers (2021–2026)

Table 50. Siemens Healthineers Recent Developments

Table 51. RapidAI Basic Information List

Table 52. RapidAI Description and Business Overview

Table 53. RapidAI Neuroimaging Software Products, Services, and Solutions

Table 54. Revenue (US$ Million) in Neuroimaging Software Business of RapidAI (2021–2026)

Table 55. RapidAI Recent Developments

Table 56. Viz.ai Basic Information List

Table 57. Viz.ai Description and Business Overview

Table 58. Viz.ai Neuroimaging Software Products, Services, and Solutions

Table 59. Revenue (US$ Million) in Neuroimaging Software Business of Viz.ai (2021–2026)

Table 60. Viz.ai Recent Developments

Table 61. Philips Basic Information List

Table 62. Philips Description and Business Overview

Table 63. Philips Neuroimaging Software Products, Services, and Solutions

Table 64. Revenue (US$ Million) in Neuroimaging Software Business of Philips (2021–2026)

Table 65. Philips Recent Developments

Table 66. Brainlab Basic Information List

Table 67. Brainlab Description and Business Overview

Table 68. Brainlab Neuroimaging Software Products, Services, and Solutions

Table 69. Revenue (US$ Million) in Neuroimaging Software Business of Brainlab (2021–2026)

Table 70. Brainlab Recent Developments

Table 71. Canon Basic Information List

Table 72. Canon Description and Business Overview

Table 73. Canon Neuroimaging Software Products, Services, and Solutions

Table 74. Revenue (US$ Million) in Neuroimaging Software Business of Canon (2021–2026)

Table 75. Canon Recent Developments

Table 76. Fujifilm Basic Information List

Table 77. Fujifilm Description and Business Overview

Table 78. Fujifilm Neuroimaging Software Products, Services, and Solutions

Table 79. Revenue (US$ Million) in Neuroimaging Software Business of Fujifilm (2021–2026)

Table 80. Fujifilm Recent Developments

Table 81. Brainomix Basic Information List

Table 82. Brainomix Description and Business Overview

Table 83. Brainomix Neuroimaging Software Products, Services, and Solutions

Table 84. Revenue (US$ Million) in Neuroimaging Software Business of Brainomix (2021–2026)

Table 85. Brainomix Recent Developments

Table 86. Bruker Basic Information List

Table 87. Bruker Description and Business Overview

Table 88. Bruker Neuroimaging Software Products, Services, and Solutions

Table 89. Revenue (US$ Million) in Neuroimaging Software Business of Bruker (2021–2026)

Table 90. Bruker Recent Developments

Table 91. Cortechs.ai Basic Information List

Table 92. Cortechs.ai Description and Business Overview

Table 93. Cortechs.ai Neuroimaging Software Products, Services, and Solutions

Table 94. Revenue (US$ Million) in Neuroimaging Software Business of Cortechs.ai (2021–2026)

Table 95. Cortechs.ai Recent Developments

Table 96. RadNet Basic Information List

Table 97. RadNet Description and Business Overview

Table 98. RadNet Neuroimaging Software Products, Services, and Solutions

Table 99. Revenue (US$ Million) in Neuroimaging Software Business of RadNet (2021–2026)

Table 100. RadNet Recent Developments

Table 101. Aidoc Basic Information List

Table 102. Aidoc Description and Business Overview

Table 103. Aidoc Neuroimaging Software Products, Services, and Solutions

Table 104. Revenue (US$ Million) in Neuroimaging Software Business of Aidoc (2021–2026)

Table 105. Aidoc Recent Developments

Table 106. ConcertAI Basic Information List

Table 107. ConcertAI Description and Business Overview

Table 108. ConcertAI Neuroimaging Software Products, Services, and Solutions

Table 109. Revenue (US$ Million) in Neuroimaging Software Business of ConcertAI (2021–2026)

Table 110. ConcertAI Recent Developments

Table 111. Qure.ai Basic Information List

Table 112. Qure.ai Description and Business Overview

Table 113. Qure.ai Neuroimaging Software Products, Services, and Solutions

Table 114. Revenue (US$ Million) in Neuroimaging Software Business of Qure.ai (2021–2026)

Table 115. Qure.ai Recent Developments

Table 116. United Imaging Intelligence Basic Information List

Table 117. United Imaging Intelligence Description and Business Overview

Table 118. United Imaging Intelligence Neuroimaging Software Products, Services, and Solutions

Table 119. Revenue (US$ Million) in Neuroimaging Software Business of United Imaging Intelligence (2021–2026)

Table 120. United Imaging Intelligence Recent Developments

Table 121. Shukun Technology Basic Information List

Table 122. Shukun Technology Description and Business Overview

Table 123. Shukun Technology Neuroimaging Software Products, Services, and Solutions

Table 124. Revenue (US$ Million) in Neuroimaging Software Business of Shukun Technology (2021–2026)

Table 125. Shukun Technology Recent Developments

Table 126. Infervision Basic Information List

Table 127. Infervision Description and Business Overview

Table 128. Infervision Neuroimaging Software Products, Services, and Solutions

Table 129. Revenue (US$ Million) in Neuroimaging Software Business of Infervision (2021–2026)

Table 130. Infervision Recent Developments

Table 131. Stryker Basic Information List

Table 132. Stryker Description and Business Overview

Table 133. Stryker Neuroimaging Software Products, Services, and Solutions

Table 134. Revenue (US$ Million) in Neuroimaging Software Business of Stryker (2021–2026)

Table 135. Stryker Recent Developments

Table 136. Nicolab Basic Information List

Table 137. Nicolab Description and Business Overview

Table 138. Nicolab Neuroimaging Software Products, Services, and Solutions

Table 139. Revenue (US$ Million) in Neuroimaging Software Business of Nicolab (2021–2026)

Table 140. Nicolab Recent Developments

Table 141. Avicenna.AI Basic Information List

Table 142. Avicenna.AI Description and Business Overview

Table 143. Avicenna.AI Neuroimaging Software Products, Services, and Solutions

Table 144. Revenue (US$ Million) in Neuroimaging Software Business of Avicenna.AI (2021–2026)

Table 145. Avicenna.AI Recent Developments

Table 146. Synaptive Medical Basic Information List

Table 147. Synaptive Medical Description and Business Overview

Table 148. Synaptive Medical Neuroimaging Software Products, Services, and Solutions

Table 149. Revenue (US$ Million) in Neuroimaging Software Business of Synaptive Medical (2021–2026)

Table 150. Synaptive Medical Recent Developments

Table 151. Quibim Basic Information List

Table 152. Quibim Description and Business Overview

Table 153. Quibim Neuroimaging Software Products, Services, and Solutions

Table 154. Revenue (US$ Million) in Neuroimaging Software Business of Quibim (2021–2026)

Table 155. Quibim Recent Developments

Table 156. Surgical Theater Basic Information List

Table 157. Surgical Theater Description and Business Overview

Table 158. Surgical Theater Neuroimaging Software Products, Services, and Solutions

Table 159. Revenue (US$ Million) in Neuroimaging Software Business of Surgical Theater (2021–2026)

Table 160. Surgical Theater Recent Developments

Table 161. mediaire Basic Information List

Table 162. mediaire Description and Business Overview

Table 163. mediaire Neuroimaging Software Products, Services, and Solutions

Table 164. Revenue (US$ Million) in Neuroimaging Software Business of mediaire (2021–2026)

Table 165. mediaire Recent Developments

Table 166. Qynapse Basic Information List

Table 167. Qynapse Description and Business Overview

Table 168. Qynapse Neuroimaging Software Products, Services, and Solutions

Table 169. Revenue (US$ Million) in Neuroimaging Software Business of Qynapse (2021–2026)

Table 170. Qynapse Recent Developments

Table 171. Thermo Fisher Basic Information List

Table 172. Thermo Fisher Description and Business Overview

Table 173. Thermo Fisher Neuroimaging Software Products, Services, and Solutions

Table 174. Revenue (US$ Million) in Neuroimaging Software Business of Thermo Fisher (2021–2026)

Table 175. Thermo Fisher Recent Developments

Table 176. Hermes Medical Solutions Basic Information List

Table 177. Hermes Medical Solutions Description and Business Overview

Table 178. Hermes Medical Solutions Neuroimaging Software Products, Services, and Solutions

Table 179. Revenue (US$ Million) in Neuroimaging Software Business of Hermes Medical Solutions (2021–2026)

Table 180. Hermes Medical Solutions Recent Developments

Table 181. Omniscient Neurotechnology Basic Information List

Table 182. Omniscient Neurotechnology Description and Business Overview

Table 183. Omniscient Neurotechnology Neuroimaging Software Products, Services, and Solutions

Table 184. Revenue (US$ Million) in Neuroimaging Software Business of Omniscient Neurotechnology (2021–2026)

Table 185. Omniscient Neurotechnology Recent Developments

Table 186. IQ-AI Basic Information List

Table 187. IQ-AI Description and Business Overview

Table 188. IQ-AI Neuroimaging Software Products, Services, and Solutions

Table 189. Revenue (US$ Million) in Neuroimaging Software Business of IQ-AI (2021–2026)

Table 190. IQ-AI Recent Developments

Table 191. Neurophet Basic Information List

Table 192. Neurophet Description and Business Overview

Table 193. Neurophet Neuroimaging Software Products, Services, and Solutions

Table 194. Revenue (US$ Million) in Neuroimaging Software Business of Neurophet (2021–2026)

Table 195. Neurophet Recent Developments

Table 196. LPIXEL Basic Information List

Table 197. LPIXEL Description and Business Overview

Table 198. LPIXEL Neuroimaging Software Products, Services, and Solutions

Table 199. Revenue (US$ Million) in Neuroimaging Software Business of LPIXEL (2021–2026)

Table 200. LPIXEL Recent Developments

Table 201. JLK Basic Information List

Table 202. JLK Description and Business Overview

Table 203. JLK Neuroimaging Software Products, Services, and Solutions

Table 204. Revenue (US$ Million) in Neuroimaging Software Business of JLK (2021–2026)

Table 205. JLK Recent Developments

Table 206. Brainreader Basic Information List

Table 207. Brainreader Description and Business Overview

Table 208. Brainreader Neuroimaging Software Products, Services, and Solutions

Table 209. Revenue (US$ Million) in Neuroimaging Software Business of Brainreader (2021–2026)

Table 210. Brainreader Recent Developments

Table 211. NordicNeuroLab Basic Information List

Table 212. NordicNeuroLab Description and Business Overview

Table 213. NordicNeuroLab Neuroimaging Software Products, Services, and Solutions

Table 214. Revenue (US$ Million) in Neuroimaging Software Business of NordicNeuroLab (2021–2026)

Table 215. NordicNeuroLab Recent Developments

Table 216. VUNO Basic Information List

Table 217. VUNO Description and Business Overview

Table 218. VUNO Neuroimaging Software Products, Services, and Solutions

Table 219. Revenue (US$ Million) in Neuroimaging Software Business of VUNO (2021–2026)

Table 220. VUNO Recent Developments

Table 221. Heuron Basic Information List

Table 222. Heuron Description and Business Overview

Table 223. Heuron Neuroimaging Software Products, Services, and Solutions

Table 224. Revenue (US$ Million) in Neuroimaging Software Business of Heuron (2021–2026)

Table 225. Heuron Recent Developments

Table 226. Coreline Soft Basic Information List

Table 227. Coreline Soft Description and Business Overview

Table 228. Coreline Soft Neuroimaging Software Products, Services, and Solutions

Table 229. Revenue (US$ Million) in Neuroimaging Software Business of Coreline Soft (2021–2026)

Table 230. Coreline Soft Recent Developments

Table 231. Cercare Medical Basic Information List

Table 232. Cercare Medical Description and Business Overview

Table 233. Cercare Medical Neuroimaging Software Products, Services, and Solutions

Table 234. Revenue (US$ Million) in Neuroimaging Software Business of Cercare Medical (2021–2026)

Table 235. Cercare Medical Recent Developments

Table 236. Revenue (US$ Million) in Neuroimaging Software Business of Company 40 (2021–2026)

Table 237. Company 40 Recent Developments

Table 238. Key Raw Materials Lists

Table 239. Key Suppliers of Raw Materials Lists

Table 240. Neuroimaging Software Downstream Customers

Table 241. Neuroimaging Software Distributors List

Table 242. Research Programs/Design for This Report

Table 243. Key Data Information from Secondary Sources

Table 244. Key Data Information from Primary Sources

List of Figures

Figure 1. Neuroimaging Software Product Picture

Figure 2. Global Neuroimaging Software Sales Value, 2021 vs 2025 vs 2032 (US$ Million)

Figure 3. Global Neuroimaging Software Sales Value (US$ Million), 2021–2032

Figure 4. Neuroimaging Software Report Years Considered

Figure 5. Global Neuroimaging Software Players Revenue Ranking (US$ Million), 2025

Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Neuroimaging Software Revenue in 2025

Figure 7. Neuroimaging Software Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 8. Advanced Post-processing and Visualization Picture

Figure 9. Quantitative Biomarkers and Volumetry Picture

Figure 10. AI Detection Picture

Figure 11. Molecular Neuroimaging Quantification Picture

Figure 12. Others Picture

Figure 13. Global Neuroimaging Software Sales Value by Type (US$ Million), 2021 vs 2025 vs 2032

Figure 14. Global Neuroimaging Software Sales Value Market Share by Type, 2025 & 2032

Figure 15. On-premise Picture

Figure 16. Cloud-based Picture

Figure 17. Hybrid Picture

Figure 18. Global Neuroimaging Software Sales Value by Deployment Model (US$ Million), 2021 vs 2025 vs 2032

Figure 19. Global Neuroimaging Software Sales Value Market Share by Deployment Model, 2025 & 2032

Figure 20. Clinical Diagnostic or Decision Support Picture

Figure 21. Clinical Trial or Drug Development Picture

Figure 22. Research Use Only Picture

Figure 23. Others Picture

Figure 24. Global Neuroimaging Software Sales Value by Intended Use (US$ Million), 2021 vs 2025 vs 2032

Figure 25. Global Neuroimaging Software Sales Value Market Share by Intended Use, 2025 & 2032

Figure 26. Product Picture of Stroke and Cerebrovascular Disease

Figure 27. Product Picture of Neurodegenerative Disease and Multiple Sclerosis

Figure 28. Product Picture of Neuro-oncology

Figure 29. Product Picture of Others

Figure 30. Global Neuroimaging Software Sales Value by Application (US$ Million), 2021 vs 2025 vs 2032

Figure 31. Global Neuroimaging Software Sales Value Market Share by Application, 2025 & 2032

Figure 32. North America Neuroimaging Software Sales Value (US$ Million), 2021–2032

Figure 33. North America Neuroimaging Software Sales Value by Country (%), 2025 vs 2032

Figure 34. Europe Neuroimaging Software Sales Value (US$ Million), 2021–2032

Figure 35. Europe Neuroimaging Software Sales Value by Country (%), 2025 vs 2032

Figure 36. Asia Pacific Neuroimaging Software Sales Value (US$ Million), 2021–2032

Figure 37. Asia Pacific Neuroimaging Software Sales Value by Subregion (%), 2025 vs 2032

Figure 38. South America Neuroimaging Software Sales Value (US$ Million), 2021–2032

Figure 39. South America Neuroimaging Software Sales Value by Country (%), 2025 vs 2032

Figure 40. Middle East & Africa Neuroimaging Software Sales Value (US$ Million), 2021–2032

Figure 41. Middle East & Africa Neuroimaging Software Sales Value by Country (%), 2025 vs 2032

Figure 42. Key Countries/Regions Neuroimaging Software Sales Value (%), 2021–2032

Figure 43. United States Neuroimaging Software Sales Value (US$ Million), 2021–2032

Figure 44. United States Neuroimaging Software Sales Value by Type (%), 2025 vs 2032

Figure 45. United States Neuroimaging Software Sales Value by Application (%), 2025 vs 2032

Figure 46. Europe Neuroimaging Software Sales Value (US$ Million), 2021–2032

Figure 47. Europe Neuroimaging Software Sales Value by Type (%), 2025 vs 2032

Figure 48. Europe Neuroimaging Software Sales Value by Application (%), 2025 vs 2032

Figure 49. China Neuroimaging Software Sales Value (US$ Million), 2021–2032

Figure 50. China Neuroimaging Software Sales Value by Type (%), 2025 vs 2032

Figure 51. China Neuroimaging Software Sales Value by Application (%), 2025 vs 2032

Figure 52. Japan Neuroimaging Software Sales Value (US$ Million), 2021–2032

Figure 53. Japan Neuroimaging Software Sales Value by Type (%), 2025 vs 2032

Figure 54. Japan Neuroimaging Software Sales Value by Application (%), 2025 vs 2032

Figure 55. South Korea Neuroimaging Software Sales Value (US$ Million), 2021–2032

Figure 56. South Korea Neuroimaging Software Sales Value by Type (%), 2025 vs 2032

Figure 57. South Korea Neuroimaging Software Sales Value by Application (%), 2025 vs 2032

Figure 58. Southeast Asia Neuroimaging Software Sales Value (US$ Million), 2021–2032

Figure 59. Southeast Asia Neuroimaging Software Sales Value by Type (%), 2025 vs 2032

Figure 60. Southeast Asia Neuroimaging Software Sales Value by Application (%), 2025 vs 2032

Figure 61. India Neuroimaging Software Sales Value (US$ Million), 2021–2032

Figure 62. India Neuroimaging Software Sales Value by Type (%), 2025 vs 2032

Figure 63. India Neuroimaging Software Sales Value by Application (%), 2025 vs 2032

Figure 64. Neuroimaging Software Value Chain

Figure 65. Neuroimaging Software Cost Structure

Figure 66. Channels of Distribution (Direct Sales, and Distribution)

Figure 67. Bottom-up and Top-down Approaches for This Report

Figure 68. Data Triangulation

Figure 69. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What was the global market size of Neuroimaging Software in 2032? zhanKai

The global market size of Neuroimaging Software in 2032 was 2638 Million USD.

Which region is expected to have the highest market share? shouQi

Which companies rank high in the global Neuroimaging Software market? shouQi

What was the global market size of Neuroimaging Software in 2026? shouQi

What is the annual compound growth rate of the global Neuroimaging Software market size from 2026 to 2032? shouQi

Related Reports

Global Neuroimaging Software Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Neuroimaging Software market is projected to grow from US$ 1326 million in 2025 to US$ 2638 million by 2032, at a CAGR of 10.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-08-14
Pages: 208
USD 4900.00
(Single User License)
Global Neuroimaging Software Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Neuroimaging Software market size was US$ 1326 million in 2025 and is forecast to reach a readjusted size of US$ 2638 million by 2032 with a CAGR of 10.3% during the forecast period 2026-2032.
Published Date: 2026-08-14
Pages: 199
USD 4250.00
(Single User License)
Global Neuroimaging Software Market Research Report 2026
The global Neuroimaging Software market was valued at US$ 1326 million in 2025 and is anticipated to reach US$ 2638 million by 2032, at a CAGR of 10.3% from 2026 to 2032.
Published Date: 2026-08-14
Pages: 209
USD 2900.00
(Single User License)
Global Neuroimaging Software Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Neuroimaging Software market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-11-17
Pages: 76
USD 4250.00
(Single User License)
Global Neuroimaging Software Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Neuroimaging Software market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-11-16
Pages: 130
USD 4900.00
(Single User License)
Global Neuroimaging Software Market Research Report 2025
The global market for Neuroimaging Software was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-02-04
Pages: 75
USD 2900.00
(Single User License)
Neuroimaging Software- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Neuroimaging Software was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-04
Pages: 95
USD 3950.00
(Single User License)

Global Neuroimaging Software Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Neuroimaging Software market is projected to grow from US$ 1326 million in 2025 to US$ 2638 million by 2032, at a CAGR of 10.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-08-14
Pages: 208
USD 4900.00 (Single User License)
Global Neuroimaging Software Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Neuroimaging Software market size was US$ 1326 million in 2025 and is forecast to reach a readjusted size of US$ 2638 million by 2032 with a CAGR of 10.3% during the forecast period 2026-2032.
Published: 2026-08-14
Pages: 199
USD 4250.00 (Single User License)
Global Neuroimaging Software Market Research Report 2026
The global Neuroimaging Software market was valued at US$ 1326 million in 2025 and is anticipated to reach US$ 2638 million by 2032, at a CAGR of 10.3% from 2026 to 2032.
Published: 2026-08-14
Pages: 209
USD 2900.00 (Single User License)
Global Neuroimaging Software Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Neuroimaging Software market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-11-17
Pages: 76
USD 4250.00 (Single User License)
Global Neuroimaging Software Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Neuroimaging Software market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-11-16
Pages: 130
USD 4900.00 (Single User License)
Global Neuroimaging Software Market Research Report 2025
The global market for Neuroimaging Software was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-02-04
Pages: 75
USD 2900.00 (Single User License)
Neuroimaging Software- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Neuroimaging Software was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-04
Pages: 95
USD 3950.00 (Single User License)